These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 36372873)

  • 1. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
    Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
    BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
    Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC.
    Wu J; Liu Z; Huang T; Wang Y; Song MM; Song T; Long G; Zhang X; Li X; Zhang L
    Mol Oncol; 2023 May; 17(5):810-824. PubMed ID: 36495130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study.
    Li M; Hou X; Zheng L; Ma Y; Li D; Lv Y; Chen J; Zheng W; Shao Y; Mou Y; Chen L
    ESMO Open; 2022 Feb; 7(1):100305. PubMed ID: 34922300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
    Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y
    Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.
    Bai K; Chen X; Qi X; Zhang Y; Zou Y; Li J; Yu L; Li Y; Jiang J; Yang Y; Liu Y; Feng S; Bu H
    J Neurooncol; 2023 Oct; 165(1):149-160. PubMed ID: 37897649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution.
    Yang H; Wen L; Zhao C; Chen J; Zhou Z; Zhou C; Cai L; Zhou C
    Heliyon; 2022 Dec; 8(12):e12374. PubMed ID: 36643302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer.
    Wang Y; Luo N; Gao Y; Wu Y; Qin X; Qi Y; Sun T; Tao R; Qi C; Liu B; Yuan S
    J Cancer Res Clin Oncol; 2023 May; 149(5):1679-1690. PubMed ID: 35583828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
    Miao Q; Zheng X; Li L; Zheng X; Zhang L; Jiang K; Wu S; Wang H; Wu B; Xu Y; Zhong Q; Zou Z; Zhang Q; Yang S; Li Y; Lin G
    J Neurooncol; 2023 Dec; 165(3):517-525. PubMed ID: 38104049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
    Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
    Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases.
    Liu X; Mei F; Fang M; Jia Y; Zhou Y; Li C; Tian P; Lu C; Li G
    Front Oncol; 2023; 13():1322635. PubMed ID: 38269023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical Value of Cerebrospinal Fluid ctDNA in Patients 
with Non-small Cell Lung Cancer Meningeal Metastasis].
    Zhang K; Dai Z; Liu S; Li D; Yang D; Cui S
    Zhongguo Fei Ai Za Zhi; 2020 Dec; 23(12):1039-1048. PubMed ID: 33357310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
    Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
    Thorac Cancer; 2023 May; 14(14):1251-1259. PubMed ID: 36977550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.
    Han X; Tang X; Zhu H; Zhu D; Zhang X; Meng X; Hua Y; Wang Z; Zhang Y; Huang W; Wang L; Yuan S; Zhang P; Gong H; Sun Y; Zhang Y; Liu Z; Dong X; Gai F; Huang Z; Zhu C; Guo J; Wang Z
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic profiling of circulating cell-free DNA from cerebrospinal fluid and paired plasma in ALK-positive lung cancer with brain metastases.
    Shi L; Guo L; Tao H; Meng Q; Tong L; Tang J; Li K; Zhang S; Liu Z
    Thorac Cancer; 2023 Jul; 14(19):1883-1893. PubMed ID: 37287428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases.
    Wijetunga NA; Goglia AG; Weinhold N; Berger MF; Cislo M; Higginson DS; Chabot K; Osman AM; Schaff L; Pentsova E; Miller AM; Powell SN; Boire A; Yang JT
    Clin Cancer Res; 2023 Feb; 29(4):775-783. PubMed ID: 36449664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer.
    Chen X; Bai K; Zhang Y; Xu Y; Huo Y; Wang S; Zou Y; Qi X; Guo R; Ou Q; Liu D; Yin S; Chen S; Bu H
    J Transl Med; 2023 May; 21(1):296. PubMed ID: 37131253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.